1. Home
  2. STLD vs INSM Comparison

STLD vs INSM Comparison

Compare STLD & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STLD
  • INSM
  • Stock Information
  • Founded
  • STLD 1993
  • INSM 1988
  • Country
  • STLD United States
  • INSM United States
  • Employees
  • STLD N/A
  • INSM N/A
  • Industry
  • STLD Steel/Iron Ore
  • INSM Biotechnology: Pharmaceutical Preparations
  • Sector
  • STLD Industrials
  • INSM Health Care
  • Exchange
  • STLD Nasdaq
  • INSM Nasdaq
  • Market Cap
  • STLD 20.1B
  • INSM 19.1B
  • IPO Year
  • STLD 1996
  • INSM 2000
  • Fundamental
  • Price
  • STLD $130.83
  • INSM $103.95
  • Analyst Decision
  • STLD Strong Buy
  • INSM Strong Buy
  • Analyst Count
  • STLD 11
  • INSM 17
  • Target Price
  • STLD $149.00
  • INSM $109.20
  • AVG Volume (30 Days)
  • STLD 1.3M
  • INSM 4.1M
  • Earning Date
  • STLD 07-21-2025
  • INSM 08-07-2025
  • Dividend Yield
  • STLD 1.53%
  • INSM N/A
  • EPS Growth
  • STLD N/A
  • INSM N/A
  • EPS
  • STLD 6.84
  • INSM N/A
  • Revenue
  • STLD $17,148,071,000.00
  • INSM $381,030,000.00
  • Revenue This Year
  • STLD $8.49
  • INSM $28.17
  • Revenue Next Year
  • STLD $6.05
  • INSM $120.09
  • P/E Ratio
  • STLD $19.11
  • INSM N/A
  • Revenue Growth
  • STLD N/A
  • INSM 20.77
  • 52 Week Low
  • STLD $103.17
  • INSM $60.40
  • 52 Week High
  • STLD $155.56
  • INSM $106.83
  • Technical
  • Relative Strength Index (RSI)
  • STLD 48.99
  • INSM 66.75
  • Support Level
  • STLD $127.60
  • INSM $101.55
  • Resistance Level
  • STLD $135.80
  • INSM $103.74
  • Average True Range (ATR)
  • STLD 3.50
  • INSM 2.58
  • MACD
  • STLD -0.43
  • INSM -0.49
  • Stochastic Oscillator
  • STLD 34.82
  • INSM 86.11

About STLD Steel Dynamics Inc.

Steel Dynamics Inc operates as a domestic steel producer and metal recycler in the United States. The company's product portfolio comprises hot rolled sheet, hot rolled plate, painted sheet products, cold rolled sheet, and others. Its reportable segments are steel operations, metals recycling operations, steel fabrication operations, and aluminum operations. Maximum revenue is generated from its steel operations segment, which consists of manufacturing various steel products and numerous coating operations. Its primary sources of revenue are currently from the manufacture and sale of steel products, the processing and sale of recycled ferrous and nonferrous metals, and the fabrication and sale of steel joists and deck products.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Share on Social Networks: